Changes to the Executive Management of Orphazyme – Anders Vadsholt to be appointed CEO
Jan 31, 2022
Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces that Chief Executive Officer (CEO) Christophe Bourdon will resign from his position as CEO at Orphazyme A/S to take on the role as CEO of LEO Pharma A/S. Effective April 1, 2022, Chief Financial Officer (CFO), Anders Vadsholt, will be appointed CEO of Orphazyme.
Changes to the Executive Management of Orphazyme
Read moreNotice to convene Extraordinary General Meeting
Jan 24, 2022
Orphazyme A/S (ORPHA.CO; ORPH) (the “Company”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announced that an Extraordinary General Meeting of the Company will be held on.
Notice to convene Extraordinary General Meeting
Appendix 1 Candidate for the Board of Directors
Read moreOrphazyme updates 2021 financial outlook
Jan 18, 2022
Orphazyme A/S (ORPHA.CO; ORPH or the “Company”), a late-stage biopharmaceutical company, today announces an update to its financial outlook for 2021 based on a review of preliminary unaudited financial results for the year ending December 31, 2021. Audited financial results for the full-year 2021 will be published on March 15, 2022.
Orphazyme updates 2021 financial outlook
Read moreOrphazyme announces changes to the Board of Directors
Dec 9, 2021
Orphazyme A/S (ORPHA.CO; ORPH or the “Company”), a late-stage biopharmaceutical company, today announces changes to the Board of Directors, following Catherine Moukheibir’s decision to step down from her position as of December 9, 2021.
Orphazyme announces changes to the Board of Directors
Read moreFinancial Calendar 2022
Nov 19, 2021
Orphazyme A/S (ORPHA.CO; ORPH or the “Company”), a late-stage biopharmaceutical company, today announces that the company expects to publish financial reports according to the following schedule.
Read moreOrphazyme establishes a U.S. At-the-Market Offering Program with Cowen
Nov 4, 2021
Orphazyme A/S (ORPHA.CO; ORPH or the “Company”), a late-stage biopharmaceutical company, today announces that it has filed with the U.S. Securities and Exchange Commission (the "SEC") a prospectus supplement (“Prospectus”) relating to a U.S. At-the-Market Offering Program, pursuant to which the Company may issue and sell American Depositary Shares ("ADSs") having an aggregate offering price of up to $50,000,000, each ADS representing one ordinary share of the Company, to be sold in the United States at market price, from time to time, at its option, in “at the market” transactions on The Nasdaq Global Select Market (the “ATM Program”). The ADSs are intended to be sold pursuant to a Sales Agreement (the "Sales Agreement") with Cowen and Company, LLC ("Cowen"). The timing of any sales will depend on a variety of factors.
Orphazyme establishes a U.S. At the Market Offering Program with Cowen
Read moreOrphazyme provides regulatory update following Type A meeting with FDA on arimoclomol in Niemann-Pick disease type C
Oct 31, 2021
Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company, today provides an update on the regulatory status in the United States of its investigational product arimoclomol for Niemann-Pick disease type C (NPC) following a recently held Type A meeting with the U.S. Food and Drug Administration (FDA).
Orphazyme provides regulatory update following Type A meeting with FDA on arimoclomol in NPC
Read moreModified long-term share-based incentive program for 2021
Oct 7, 2021
Orphazyme A/S (ORPHA.CO (DK); ORPH (US)), a late-stage biopharmaceutical company, has today introduced a modified long-term incentive program for 2021 (the “LTIP”) with the view to retaining members of the Executive Management and other employees of the Group, while also creating an incentive for a positive share price development and corporate performance for the benefit of the Company’s shareholders.
Modified long term share based incentive program for 2021
Read moreOrphazyme provides regulatory and financial updates
Oct 5, 2021
Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company, today announces regulatory updates for its investigational drug candidate, arimoclomol, for which it is seeking marketing authorization in both Europe and the United States for the treatment of Niemann-Pick disease Type C (NPC). The company also announces that it now expects to end 2021 with a cash position of no less than DKK 80 million compared to prior guidance of approximately DKK 50 million.
Orphazyme provides regulatory and financial updates
Read moreOrphazyme reports business highlights and financial results in Interim Report First Half 2021
Aug 31, 2021
Orphazyme A/S (ORPHA.CO; ORPH) (“the Company”), a late-stage biopharmaceutical company, today announces its Interim Report First Half 2021 for the period January 1 – June 30, 2021.
Orphazyme reports business highlights and financial results in Interim Report First Half 2021
Read more